PPARG and cancer: In addition, it has been shown that PPARG agonists also enhance the activity of Histone deacetylase Inhibitors (HDACi), which may act as epigenetic regulators to exert anti-cancer effects (Mishra et al., 2014; Aouali et al., 2015).